vs
Cipher Mining Inc.（CIFR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Cipher Mining Inc.的季度营收约是REGENXBIO Inc.的2.0倍（$59.7M vs $30.3M），REGENXBIO Inc.净利率更高（-221.3% vs -1229.6%，领先1008.3%），REGENXBIO Inc.同比增速更快（43.0% vs 41.4%），REGENXBIO Inc.自由现金流更多（$-52.8M vs $-695.9M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 11.4%）
Cipher Mining Inc.是总部位于美国的比特币挖矿生态运营企业，当前正全力发展加密货币相关业务，深耕加密行业上游基础设施赛道，依托技术及合规优势构建稳定高效的挖矿服务体系。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CIFR vs RGNX — 直观对比
营收规模更大
CIFR
是对方的2.0倍
$30.3M
营收增速更快
RGNX
高出1.6%
41.4%
净利率更高
RGNX
高出1008.3%
-1229.6%
自由现金流更多
RGNX
多$643.1M
$-695.9M
两年增速更快
RGNX
近两年复合增速
11.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $59.7M | $30.3M |
| 净利润 | $-734.2M | $-67.1M |
| 毛利率 | 59.4% | — |
| 营业利润率 | -503.4% | -190.0% |
| 净利率 | -1229.6% | -221.3% |
| 营收同比 | 41.4% | 43.0% |
| 净利润同比 | -4293.1% | -31.2% |
| 每股收益（稀释后） | $-1.91 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CIFRRGNX
| Q4 25 | $59.7M | $30.3M | ||
| Q3 25 | $71.7M | $29.7M | ||
| Q2 25 | $43.6M | $21.4M | ||
| Q1 25 | $49.0M | $89.0M | ||
| Q4 24 | $42.2M | $21.2M | ||
| Q3 24 | $24.1M | $24.2M | ||
| Q2 24 | $36.8M | $22.3M | ||
| Q1 24 | $48.1M | $15.6M |
净利润CIFRRGNX
| Q4 25 | $-734.2M | $-67.1M | ||
| Q3 25 | $-3.3M | $-61.9M | ||
| Q2 25 | $-45.8M | $-70.9M | ||
| Q1 25 | $-39.0M | $6.1M | ||
| Q4 24 | $17.5M | $-51.2M | ||
| Q3 24 | $-86.8M | $-59.6M | ||
| Q2 24 | $-15.3M | $-53.0M | ||
| Q1 24 | $39.9M | $-63.3M |
毛利率CIFRRGNX
| Q4 25 | 59.4% | — | ||
| Q3 25 | 62.7% | — | ||
| Q2 25 | 64.8% | — | ||
| Q1 25 | 69.6% | — | ||
| Q4 24 | 56.9% | 70.2% | ||
| Q3 24 | 37.5% | 48.8% | ||
| Q2 24 | 61.2% | 52.5% | ||
| Q1 24 | 69.2% | 72.6% |
营业利润率CIFRRGNX
| Q4 25 | -503.4% | -190.0% | ||
| Q3 25 | -52.5% | -176.3% | ||
| Q2 25 | -103.9% | -296.3% | ||
| Q1 25 | -77.8% | 13.6% | ||
| Q4 24 | 40.5% | -242.1% | ||
| Q3 24 | -379.2% | -256.6% | ||
| Q2 24 | -43.9% | -251.3% | ||
| Q1 24 | 97.2% | -408.8% |
净利率CIFRRGNX
| Q4 25 | -1229.6% | -221.3% | ||
| Q3 25 | -4.6% | -208.3% | ||
| Q2 25 | -105.1% | -331.8% | ||
| Q1 25 | -79.6% | 6.8% | ||
| Q4 24 | 41.5% | -241.3% | ||
| Q3 24 | -359.9% | -246.3% | ||
| Q2 24 | -41.5% | -237.7% | ||
| Q1 24 | 82.9% | -405.4% |
每股收益（稀释后）CIFRRGNX
| Q4 25 | $-1.91 | $-1.30 | ||
| Q3 25 | $-0.01 | $-1.20 | ||
| Q2 25 | $-0.12 | $-1.38 | ||
| Q1 25 | $-0.11 | $0.12 | ||
| Q4 24 | $0.04 | $-0.99 | ||
| Q3 24 | $-0.26 | $-1.17 | ||
| Q2 24 | $-0.05 | $-1.05 | ||
| Q1 24 | $0.13 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $628.3M | $230.1M |
| 总债务越低越好 | $2.7B | — |
| 股东权益账面价值 | $805.5M | $102.7M |
| 总资产 | $4.3B | $453.0M |
| 负债/权益比越低杠杆越低 | 3.37× | — |
8季度趋势，按日历期对齐
现金及短期投资CIFRRGNX
| Q4 25 | $628.3M | $230.1M | ||
| Q3 25 | $1.2B | $274.2M | ||
| Q2 25 | $62.7M | $323.3M | ||
| Q1 25 | $23.2M | $267.9M | ||
| Q4 24 | $5.6M | $234.7M | ||
| Q3 24 | $25.3M | $255.5M | ||
| Q2 24 | $122.6M | $290.4M | ||
| Q1 24 | $88.7M | $338.7M |
总债务CIFRRGNX
| Q4 25 | $2.7B | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $167.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CIFRRGNX
| Q4 25 | $805.5M | $102.7M | ||
| Q3 25 | $783.2M | $161.5M | ||
| Q2 25 | $748.9M | $213.7M | ||
| Q1 25 | $734.8M | $274.2M | ||
| Q4 24 | $682.0M | $259.7M | ||
| Q3 24 | $672.0M | $301.4M | ||
| Q2 24 | $690.8M | $348.3M | ||
| Q1 24 | $600.9M | $390.7M |
总资产CIFRRGNX
| Q4 25 | $4.3B | $453.0M | ||
| Q3 25 | $2.8B | $525.2M | ||
| Q2 25 | $1.0B | $581.0M | ||
| Q1 25 | $913.8M | $490.9M | ||
| Q4 24 | $855.4M | $466.0M | ||
| Q3 24 | $775.4M | $519.1M | ||
| Q2 24 | $775.6M | $569.4M | ||
| Q1 24 | $677.1M | $629.2M |
负债/权益比CIFRRGNX
| Q4 25 | 3.37× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-207.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-695.9M | $-52.8M |
| 自由现金流率自由现金流/营收 | -1165.4% | -174.0% |
| 资本支出强度资本支出/营收 | 817.1% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.1B | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CIFRRGNX
| Q4 25 | $-207.9M | $-52.3M | ||
| Q3 25 | $-50.1M | $-56.0M | ||
| Q2 25 | $-56.2M | $-49.3M | ||
| Q1 25 | $-47.2M | $33.6M | ||
| Q4 24 | $-87.5M | $-31.6M | ||
| Q3 24 | $-6.5M | $-40.5M | ||
| Q2 24 | $-25.4M | $-45.5M | ||
| Q1 24 | $-26.6M | $-55.5M |
自由现金流CIFRRGNX
| Q4 25 | $-695.9M | $-52.8M | ||
| Q3 25 | $-256.2M | $-56.5M | ||
| Q2 25 | $-87.5M | $-49.7M | ||
| Q1 25 | $-71.8M | $32.6M | ||
| Q4 24 | $-227.0M | $-32.7M | ||
| Q3 24 | $-83.2M | $-40.9M | ||
| Q2 24 | $-33.2M | $-46.0M | ||
| Q1 24 | $-34.5M | $-56.0M |
自由现金流率CIFRRGNX
| Q4 25 | -1165.4% | -174.0% | ||
| Q3 25 | -357.3% | -189.9% | ||
| Q2 25 | -200.9% | -232.8% | ||
| Q1 25 | -146.7% | 36.6% | ||
| Q4 24 | -537.6% | -154.2% | ||
| Q3 24 | -345.0% | -168.9% | ||
| Q2 24 | -90.2% | -206.2% | ||
| Q1 24 | -71.7% | -358.5% |
资本支出强度CIFRRGNX
| Q4 25 | 817.1% | 1.7% | ||
| Q3 25 | 287.5% | 1.7% | ||
| Q2 25 | 71.8% | 1.8% | ||
| Q1 25 | 50.2% | 1.2% | ||
| Q4 24 | 330.4% | 5.1% | ||
| Q3 24 | 317.8% | 1.3% | ||
| Q2 24 | 21.4% | 2.1% | ||
| Q1 24 | 16.4% | 3.6% |
现金转化率CIFRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | -5.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CIFR
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
